Hepatitis-associated aplastic anemia from workout supplement: Rare but potentially fatal entity.
Hematology
aplastic anemia
gastroenterology/hepatology
hepatitis
workout supplement
Journal
SAGE open medical case reports
ISSN: 2050-313X
Titre abrégé: SAGE Open Med Case Rep
Pays: England
ID NLM: 101638686
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
01
2019
accepted:
31
12
2019
entrez:
8
2
2020
pubmed:
8
2
2020
medline:
8
2
2020
Statut:
epublish
Résumé
Hepatitis-associated aplastic anemia (HAAA) is a rare clinical syndrome characterized by bone marrow failure 1-3 months after development of hepatitis. Untreated, hepatitis-associated aplastic anemia has poor outcome and the mainstay of treatment remains either bone marrow transplant or immunosuppressive therapy. A previously healthy 21-year-old man presented with a 1-week history of right upper quadrant pain and jaundice. Admission labs revealed mixed hyperbilirubinemia and elevated transaminases ranging in 2000s IU/dl. Extensive workup for etiologies of acute hepatitis including viruses, autoimmune, toxins etc. were negative. He admitted to taking "Dust V2," a workout supplement, for 4 months prior to the presentation. His liver function tests started to improve after conservative treatment. Two months after his discharge, he was found to have severe pancytopenia on routine labs. Bone marrow biopsy revealed hypocellular marrow consistent with aplastic anemia. Extensive workup for etiologies of aplastic anemia were negative. On literature review, none of the components of the supplement were found to cause aplastic anemia. A diagnosis of hepatitis-associated aplastic anemia was made as there was a lag time before development of anemia. His counts failed to improve despite treatment with filgrastim and he was referred for hematopoietic cell transplant.
Identifiants
pubmed: 32030129
doi: 10.1177/2050313X20901937
pii: 10.1177_2050313X20901937
pmc: PMC6977214
doi:
Types de publication
Case Reports
Langues
eng
Pagination
2050313X20901937Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Hematology Am Soc Hematol Educ Program. 2012;2012:292-300
pubmed: 23233595
J Pediatr Gastroenterol Nutr. 2017 Jan;64(1):e7-e12
pubmed: 28030425
Case Reports Hepatol. 2014;2014:216570
pubmed: 25587471
Food Addit Contam Part A Chem Anal Control Expo Risk Assess. 2019 Sep;36(9):1273-1288
pubmed: 31294678
Semin Hematol. 2013 Apr;50(2):156-64
pubmed: 24216172
Bone Marrow Transplant. 2001 Jan;27(2):183-90
pubmed: 11281388
Bone Marrow Transplant. 2013 Feb;48(2):168-73
pubmed: 23208312
Lancet. 1995 Jul 22;346(8969):228-32
pubmed: 7616805
Br J Haematol. 2010 Jun;149(6):890-5
pubmed: 20456352
N Engl J Med. 2015 Oct 15;373(16):1531-40
pubmed: 26465986
N Engl J Med. 1997 Apr 10;336(15):1059-64
pubmed: 9091802
Aliment Pharmacol Ther. 2009 Sep 1;30(5):436-43
pubmed: 19508613
Br J Haematol. 2007 Feb;136(4):549-64
pubmed: 17214739